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Non-compaction of the left ventricular myocardium (LVNC) has gained increasing recognition during the last 25 years. There is a morpho-
logical trait of the myocardial structure with a spectrum from normal variants to the pathological phenotype of LVNC, which reflects the
embryogenic structure of the human heart due to an arrest in the compaction process during the first trimester. It must be cautioned not to
overdiagnose LVNC: the morphological spectrum of trabeculations, from normal variants to pathological trabeculations with the morpho-
logical feature of LVNC must be carefully considered. The classical triad of complications are heart failure, arrhythmias, including sudden
cardiac death, and systemic embolic events. Non-compaction of the left ventricular myocardium can occur in isolation or in association
with congenital heart defects (CHDs), genetic syndromes, and neuromuscular disorders among others. The clinical spectrum is wide and
the outcome is more favourable than in previously described populations with a negative selection bias. Familial occurrence is frequent
with autosomal dominant and X-linked transmissions. Different mutations in sarcomere protein genes were identified and there seems
to be a shared molecular aetiology of different cardiomyopathic phenotypes, including LVNC, hypertrophic and dilated cardiomyopathies.
Thus, genetic heterogeneity, with an overlap of different phenotypes, and the variability of hereditary patterns, raise the questions
whether there is a morphological trait from dilated/hypertrophic cardiomyopathy to LVNC and what are the triggers and modifiers to
develop either dilated, hypertrophic cardiomyopathy, or LVNC in patients with the same mutation. The variety in clinical presentation,
the genetic heterogeneity, and the phenotype of the first transgenetic animal model of an LVNC-associated mutation question the hypothesis
that LVNC be a distinct cardiomyopathy: it seems to be rather a distinct phenotype or phenotypic, morphological expression of different
underlying diseases than a distinct cardiomyopathy.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Cardiomyopathy † Non-compaction † Heart failure † Genetics † Echocardiography
Introduction
Non-compaction of the ventricular myocardium (LVNC) has
gained increasing awareness and attention and its diagnosis has
moved from the autopsy table or previously poorly recognized
to a widely recognized cardiomyopathy.1– 3 The exponential
increase in publications reflects increasing interest of this fascinat-
ing myocardial phenotype.4 This raises the question whether
advances in non-invasive diagnostic technologies led to better deli-
neation of the morphological appearance of the myocardium or
whether LVNC is overdiagnosed and the diagnostic criteria are
too sensitive. The goal of this article is to review developmental
consideration, different diagnostic criteria, genetic considerations,
outcomes, and therapeutic implications of this cardiomyopathic
phenotype with genetic heterogeneity and to answer the question
whether LVNC is a distinct cardiomyopathy or a distinct myocar-
dial phenotype of different underlying diseases.
Historical aspect
Spongy appearance of the myocardium was first identified in a
variety of congenital heart defects (CHDs), with the first descrip-
tion published by Grant in 1926.5,6 It is Dusek et al.,7 however, who
get credited with bringing the entity of spongy myocardium into
clinical focus although these early cases are hardly representative
of the entity now described as LVNC. The first description of an
isolated, rare myocardial anomaly in the absence of any other
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structural heart disease was published by Engberding.8 The Zurich
group confirmed Engberding’s findings and published case reports
describing echocardiographic, angiographic, and pathological ana-
tomical findings.9,10 These early reports appreciated the persist-
ence of embryonic myocardial structures, but it was Chin et al.11
who introduced the term ‘isolated non-compaction of left ventricular
myocardium’ and recognised the underlying arrest of the normal
compaction process during embryogenesis.
Developmental considerations
Understanding of the ontogenetic development of the myocardium
is critical to appreciate the morphological appearance of LVNC.
There is some controversy whether LVNC is congenital due to
an arrest of the normal compaction process of the developing
myocardium or LVNC is acquired.
The development of the heart follows the same pattern in all
vertebrates from fish to human, where the myocardial maturation
undergoes complex changes during the evolutionary development.
Landmark articles very nicely illustrate the development of the
myocardial architecture which passes through four distinct
steps:6,12 (i) early heart tube, (ii) emergence of trabeculations,
(iii) trabecular remodelling, (iv) development of the multilayered
spiral system. Emergence of trabeculations and trabecular remo-
delling are the key steps to understand LVNC.
Emergence of trabeculations
Trabeculations in the human embryo emerge after looping of the
primitive heart tube at the end of the fourth week of gestation
(length of the embryo 4 mm) (Figure 1).12 Only early trabecula-
tions effectively increase surface area, enabling the myocardial
mass to increase in the absence of an epicardial coronary circula-
tion. The trabeculation patterns are ventricle-specific: the trabecu-
lations in the LV are generally thicker and the corresponding
intertrabecular spaces are larger at this embryonic stage. When
this myocardial pattern persists postnatally, the morphological
appearance strongly resembles the spongy myocardium seen in
non-mammalian vertebrates (e.g. reptiles, fish, amphibians).6
Trabecular remodelling
Trabecular remodelling starts after completion of ventricular sep-
tation (at 8 weeks of gestation in human) (Figure 1). Increase in ven-
tricular volumes results in compression of the trabeculations with
an increase in the thickness of the compacted myocardium.12
Rearrangement of the endocardial trabeculations is specific for
the ventricles and the species. In the mammalian heart, some of
the luminal trabeculations coalesce to produce the anterior and
posterior papillary muscles of the mitral valve and apical trabecula-
tions transform into fine honeycomb-like reliefs on the inner ven-
tricular surface.12 This special aspect must be appreciated when
Figure 1 Parietal view of sagitally dissected human embryonic left ventricles showing the process of normal trabecular compaction. (A) Abun-
dant fine trabeculations present at 6 weeks. (B) The trabeculae start to solidify at the base of the heart, contributing to added thickness of the
compacted layer; initiation of this process coincides with the development of the epicardial coronary system. (C ) The compact layer forms most
of the myocardium mass after completion of compaction in the early foetal period. Scale bars 100 mm (A and B), 1 mm (C). Modified reproduc-
tion from Isolated left ventricular non-compaction: a distinct cardiomyopathy? Varnava AM Heart 2001; 86:599–600,47 copyright 2001, with
permission from BMJ Publishing Group Ltd.
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the morphological appearance of the LV myocardium is described
and LVNC is considered.
The compaction process or trabecular remodelling coincides
with the invasion of the epicardial coronary arteries and vascular-
ization of the myocardium. It gradually progresses from the epicar-
dium to the endocardium, from the base to the apex and from the
septum to the free wall in the LV, and is more pronounced in
the LV than in the right ventricle.12 Thus, the time of arrest of
the normal embryonic myocardial maturation determines the
severity and extension of LVNC; the ventricular apex is always
involved as the compaction process concludes in the ventricular
apex.
Non-compaction of the
myocardium: congenital
or acquired?
Evolutionary changes during morphogenesis strongly suggest that
LVNC reflects impaired/arrested compaction of the developing
myocardium.6,7,11,13,14 There is a controversy, however, if LVNC
can also be acquired.15 The discussion against the developmental
hypothesis comes from serial echocardiographic studies where
LVNC was not diagnosed on initial echocardiogram but was
becoming evident in subsequent examinations.
The weight of evidence, based on the developmental changes,
strongly supports the hypothesis that LVNC reflects an abnormal-
ity in the early myocardial morphogenesis or failure of full matu-
ration of the compacted myocardium.6 Recent advances in
genetics, however, raise the question whether LVNC can also
develop postnatally. The morphological features of dilated and
hypertrophic cardiomyopathy are not present at birth, but they
develop during life. Patients with dilated cardiomyopathy, hyper-
trophic cardiomyopathy, and LVNC share common mutations in
sarcomere protein genes. This common genetic background
raises the hypothesis whether LVNC may also develop later in life.
Terminology
Dusek et al.7 were one of the first who described the morphologi-
cal appearance of the myocardium in five hearts with different
pathologies as postnatal persistence of spongy myocardium with
embryological blood supply. Others invoked this concept of evol-
utionary persistence of the spongy myocardium which resembled a
loosely interwoven mesh of trabeculated muscle fibres seen in the
embryo and in cold-blooded vertebrates. Many other terms were
introduced but were not widely used.
Three terms need further discussion and clarification: non-
compaction, hypertrabeculation, and persistent sinusoids. It was
Chin et al.11 who first introduced the term non-compaction.
They argued that the descriptive term ‘spongy myocardium’ has
the virtue of precedence. The term non-compaction, however,
underscores the hypothesis of an arrest of the normal compaction
process of the loosely interwoven mesh of muscle fibres in the
embryo. Second, some hearts with ‘spongy myocardium’ have
heavy trabeculations in the affected ventricle, but it does not
follow that every heavily trabeculated ventricle has a ‘spongy
myocardium’.11
The term ‘persistent sinusoids’ is not correct. Persistent, myo-
cardial sinusoids describe ventriculo-coronary arterial communi-
cations or intertrabecular spaces connecting the ventricular
cavity with the epicardial coronary artery system through the capil-
lary bed. They are usually seen in pulmonary atresia with intact
ventricular septum.6 The histological appearance is completely
different from non-compaction and clinical and developmental
data support the evidence of a primary coronary vascular
anomaly for the development of persistent myocardial sinusoids.
In contrast, the intertrabecular recesses and their troughs are
lined with endothelium in the non-compacted myocardium.
The term hypertrabeculation is not correct either. Hypertrabe-
culation implies an increased number of normally formed trabecu-
lations. The histological appearance of LVNC, however, is far
beyond normal.6,16
Developmental considerations and evolutionary evidence do
not support either the term hypertrabeculation or persistent
myocardial sinusoids to describe the distinct morphological
feature of non-compaction. Failure of trabecular remodelling is
best described by the term ‘non-compaction’ to illustrate the
impaired compaction process and failure of myocardial maturation
during embryogenesis.6,11,12 Scientific statements using the term
‘non-compaction’ acknowledge myocardial morphogenesis.1– 3
Classification of cardiomyopathies
The 1995 World Health Organization (WHO)/International
Society and Federation of Cardiology Task Force on the definition
and classification of cardiomyopathies did not classify non-
compaction as a distinct cardiomyopathy but it was rather
grouped as an unclassified cardiomyopathy.3 A causative, genetic
approach would be logical because many cardiomyopathies are
caused by mutations in genes encoding various cardiac proteins.17
The American Heart Association recognized the rapid evolution of
molecular genetics in cardiology and classified LVNC as primary,
genetic cardiomyopathy.2 In contrast, a position statement of the
European Society of Cardiology classified LVNC as ‘unclassified
cardiomyopathy’ because it is not clear whether it is a separate
cardiomyopathy or merely a morphological trait shared by many
phenotypically distinct cardiomyopathies.1
Diagnostic criteria
Normal variants
Characterization of the normal myocardial structure is the first
step before definition of a pathological appearance of the myocar-
dium. Boyd et al.18 reported the frequency and localization of
prominent LV trabeculations at autopsy in 474 normal hearts.
Prominent trabeculations were observed in 68% of these hearts,
and 53% of them exhibited two or more. More than three promi-
nent trabeculations were observed in only 3%, but none of the
hearts had more than five. Most of the trabeculations (85%)
were septomarginal bundles inserting into both the free wall and
the septum.
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Echocardiography is the diagnostic modality of first choice to
describe myocardial pathologies. However, recent advancements
in echocardiography, such as second harmonic imaging, have per-
mitted detection of previously unrecognized anatomical structures
of the normal heart. This raises the question whether structures,
such as fine trabeculations, are normal, a normal variant or
abnormal. The ratio of trabeculated/compacted myocardium was
1.29+0.4 in normal and pathological hearts and much lower
than in hearts with non-compacted myocardium.19 An expert car-
diologist and echocardiography operator, however, are qualified to
recognize the anatomical trait of LVNC and to separate normal
variants of the myocardial appearance from LVNC.
Non-compaction
Chin et al.11 proposed echocardiographic diagnostic criteria and
brought the condition to our attention (Table 1). They quantified
the depth of penetration of the intertrabecular recesses relative
to the posterior wall thickness at end-diastole and calculated the
X-ratio to Y-ratio. This method was validated against a control
group of eight subjects with normal echocardiographic studies,
which did not disclose the progressive decrease in the X-to-Y
ratio from the level of the mitral valve to the apex.
The Zurich group defined echocardiographic diagnostic criteria
for isolated LVNC and validated them with patho-anatomical heart
preparations (Figure 2).13 Chin’s and Jenni’s criteria require a two-
layered myocardial structure with a compacted epicardial layer and
a much thicker, non-compacted endocardial layer. In contrast to
Chin et al., the Zurich group relied on measurements at end-
systole to assess the thickness of the two layers best visualized
at end-systole. Three additional criteria were added to diagnose
isolated LVNC (Table 1). Their diagnostic criteria of LVNC were
validated in valvular or hypertensive heart disease or dilated
cardiomyopathy (Figure 3). Although some non-compaction cri-
teria were occasionally found in other heart diseases, the combi-
nation of all criteria was very specific, and all criteria of
non-compaction were rarely met (,5%) in other diseases.20
Sto¨llberger et al.21 depart from the above diagnostic approach to
visualize the two distinct endocardial and epicardial layers
(Table 1). The Vienna group modified their diagnostic criteria
during the last years and shifted away from their original descrip-
tion. They also prefer to describe the phenotype as ‘LV hypertra-
beculation’ rather than ‘non-compaction’, although they now add
‘non-compaction’ to their description.15,21
Limitations of echocardiographic criteria
Kohli et al.22 challenged these three diagnostic criteria (Table 1).
There was a poor correlation between the three echocardio-
graphic definitions: 24% of the study population fulfilled one or
more echocardiographic definitions for LVNC, while only 30%
fulfilled all three criteria. This poor correlation is not surprising:
the method of the morphological description differs in the defi-
nition of abnormal trabeculations, in the echo planes and in the
phase of the cardiac cycle in which the morphology is described
(Table 1).11,13,21,22
More surprisingly, 8% of apparently healthy individuals also sat-
isfied one or more diagnostic criteria for LVNC; interestingly, four
of these individuals were black.22 This raises the question whether
the current diagnostic criteria are too sensitive, in particular for
black individuals, non-compaction is overdiagnosed or the retro-
spective study design was a limitation (the patients were studied
without specific focus on non-compaction).22 On the other
hand, the extent of the myocardial meshwork, with fine trabecula-
tions at one end and LVNC at the other end of the spectrum, may
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Diagnostic criteria for left ventricular
non-compaction
Echocardiography
Chin et al.11
Two-layered structure of the myocardium (epicardial
compacted, endocardial non-compacted layer)
Determination of the X-to-Y ratio (≤0.5)
X—Distance between the epicardial surface and through of
intertrabecular recess
Y—Distance between epicardial surface and peak of
trabeculation
Acquisition of the images: parasternal short-axis view,
measurements of the X-to-Y ratio at end-diastole
Jenni et al.13
Thickened myocardium with a two-layered structure consisting
of a thin compacted epicardial layer/band (C) and a much
thicker, non-compacted endocardial layer (N) or trabecular
meshwork with deep endomyocardial spaces; N/C ratio .2.0
Predominant location of the pathology: mid-lateral, mid-inferior,
and apex
Colour Doppler evidence of deep intertrabecular recesses filled
with blood from the left ventricular cavity
Absence of coexisting cardiac abnormalities (in the presence of
isolated LVNC)
Acquisition of the images: short-axis views, measurements of the
N/C ratio at end-systole
Sto¨llberger et al.15,21
More than three trabeculations protruding from the left
ventricular wall, located apically to the papillary muscles and
visible in one image plane
Trabeculations with the same echogenicity as the myocardium
and synchronous movement with ventricular contractions
Perfusion of the intertrabecular spaces from the left ventricular
cavity
Ratio of non-compacted to non-compacted segment .2.0 at
end-diastole (this criterion was introduced later)
Acquisition of the images: apical four chamber view; angulation of
the transducer and acquisition of pictures in atypical views to
obtain the technically best picture quality for differentiation
between false chords/aberrant bands and trabeculations
Diagnostic criteria have changed during the last years
Magnetic resonance imaging
Petersen et al.26
Ratio between the non-compacted and compacted layer .2.3
Measurement: at end-diastole
Jacquier et al.27
Trabeculated left ventricular mass .20% of the global left
ventricular mass
Measurement: left ventricular trabeculation and global/
compacted LV mass were defined at end-diastole
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represent a continuous morphological trait and spectrum. Promi-
nent trabeculations in heart failure patients could be no more
than an incidental finding or a normal variant. The most important
question remains when fine trabeculations are a normal variant and
when they become pathological.
Echocardiographic pitfalls
Echocardiography depends on the skills, experience, and know-
ledge of the investigator. Oblique images obtained off-axis or
images in the parasternal short-axis view, which are not perpen-
dicular to the LV long axis, can produce the morphological appear-
ance of prominent trabeculations and mimic LVNC. It is critical to
obtain images that are not foreshortened and are perpendicular to
the ventricular long axis. In addition, there are inherent challenges
to image the ventricular apex and misdiagnoses are not rare. Con-
trast echocardiogram is useful to better image intertrabecular
spaces (Figure 4).
Interpretation of trabeculations adjacent to the papillary muscles
and at the apex is challenging and embryogenic considerations must
be taken into account when the myocardial pattern is described:
some of the luminal trabeculations coalesce to produce the anterior
and posterior papillary muscles of the mitral valve and apical trabe-
culations transform into fine honeycomb-like reliefs on the inner
ventricular surface.6,12 These developmental aspects must be
appreciated when LVNC is considered.
New echocardiographic technique, such as tissue Doppler
imaging, strain and strain rate, and speckle tracking, may help to
evaluate the functional impact of an abnormal myocardial architec-
ture and enable the clinician to distinguish between normally trabe-
culated myocardium from LVNC.23,24 Left ventricular twist was
determined by speckle tracking echocardiography.25 Rotation
was clockwise at the base and counterclockwise at the apex in
all controls and patients with dilated cardiomyopathy. In contrast,
the LV base and apex rotated in the same direction in all non-
compaction patients. Thus, LV solid body rotation/twist may be a
new objective and quantitative, functional diagnostic criterion for
non-compaction.25
Cardiac magnetic resonance imaging
Cardiac magnetic resonance imaging (MRI) has been increasingly
used to describe the morphological appearance of the myocar-
dium. Petersen et al.26 tested the accuracy of MRI in distinguishing
pathological LVNC from lesser degrees of trabecular layering seen
in those with normal hearts, and in those with LV hypertrophy and
cardiomyopathies. Areas of non-compaction were common
and occurred more frequently in all groups studied in the apical
and lateral, rather than in basal and septal segments as reported
in echocardiographic studies. A non-compacted to compacted
ratio of .2.3 in diastole distinguished pathological non-
Figure 2 (A) Parasternal short-axis view of a patient with isolated LVNC. The end-systolic still-frame shows the two-layered structured of
the thickened myocardium. (B) To quantify the thickness of the non-compacted layer at the site of maximal thickness, the end-systolic ratio of
the non-compacted (NC) to compacted (C ) layer is determined. (C) Apical four-chamber view (end-diastolic still frame) showing the inter-
trabecular recesses filled with blood from the left ventricular cavity. (D) Transmural, histological section (haematoxylin and eosin stain). The
endocardial, non-compacted layer is covered with endocardium and communicates with the LV cavity. Courtesy of Dr J. Schneider,
University Hospital, Zurich.
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compaction with values for sensitivity and specificity, and positive
and negative predictions of 86, 99, 75, and 99%, respectively.
Jacquier et al.27 took a different approach to characterize the LV
myocardium. Total LV mass and trabeculated LV mass were
measured in control subjects, in patients with dilated cardiomyopa-
thy, hypertrophic cardiomyopathy, and LVNC. The percentage of
trabeculated LV mass was three times higher in patients with
LVNC than in those with dilated and hypertrophic cardiomyopathy
Figure 3 Cross-section views of a normal heart (A), hypertrophic cardiomyopathy (B), and isolated LVNC (C). Transsectional view from
anterior on the dorsal half of the heart with severe isolated LVNC (D). The endocardial surface of the specimens (A) and (B) is smooth.
(C) demonstrates the two-layered structured of the myocardial wall with an epicardial compacted (C) and a more than twice as thick endo-
cardial, non-compacted (NC) layer. Note marked fibroelastosis of the LV in (C and D). (A and C) Courtesy of Dr P. Vogt, University Hospital,
Zurich. (B and D) Courtesy of Dr J. Schneider, University Hospital, Zurich. LV, left ventricle. RV, right ventricle.
Figure 4 Apical four-chamber view in a patient with isolated LVNC: (A) without contrast; (B) with contrast showing the intertrabecular
recesses of the endocardial non-compacted layer.
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or in controls. Interestingly, the LV compacted mass was the same
in patients with dilated cardiomyopathy and LV non-compaction
and in healthy controls.27
How to diagnose non-compaction
of the left ventricular
myocardium?
Echocardiography and cardiac MRI studies confirm that the degree
of trabeculated LV myocardium is far more frequent than pre-
viously thought; this supports the concept of a continuous trait
between normal and pathological appearance of the myocar-
dium.6,19,20,26–28 We require the presence of a thickened myocar-
dial wall with the non-compacted layer being at least twice as thick
as the compacted layer (Table 1). Speckle tracking is helpful to
describe abnormal LV body rotation/twist.25 Echocardiography,
however, is investigator dependent and has limitations and pitfalls.
As the quality of the echocardiographic images improves and more
details of the myocardial structure can be imaged, we hypothesize
that multimodality imaging, including echocardiography and cardiac
MRI, is required to confirm or to exclude LVNC (Table 2). Diagno-
sis by echocardiography and cardiac MRI must be concordant. This
concept may help not to overdiagnose LVNC, but it has to be
validated.
Differential diagnosis
The differential diagnosis can be challenging and includes apical
form of hypertrophic cardiomyopathy, a combination of both
apical hypertrophic cardiomyopathy and LVNC, hypertensive car-
diomyopathy, endocardial fibroelastosis, abnormal chords, apical
thrombus, or tumours among others (Figure 3). Differential diagno-
sis between dilated cardiomyopathy and LVNC can be a challenge
in dilated ventricles. The diagnostic criteria for LVNC, however,
are still fulfilled in a dilated LV if the diagnosis is LVNC; this is
evident in patients with LVNC during follow-up in whom the
first examination revealed normal size and systolic function of
the LV.
Genetics of non-compaction of the
left ventricular myocardium
Non-compaction of the left ventricular myocardium is a genetically
heterogeneous disorder with a sporadic and familial form.11,29,30 It
can be linked to mutations in mitochondrial, cytoskeletal, Z-line,
and sarcomeric proteins.31 Autosomal dominant inheritance
seems to be more common than X-linked inheritance.32–34 Famil-
ial recurrence widely varies between 18 and 50% of the cases but
there are limitations due to the retrospective study design.11,30,33,35
Autosomal recessive inheritance was also observed.36 This high
rate of transmission emphasizes the importance of detailed pedi-
gree analysis and justifies screening of all first-degree family
members of affected individuals.
Point mutations in G4.5/a-dystrobrevin/
ZASP
Mutations in the G4.5 gene, which maps to chromosome Xq28,
result in a wide spectrum of severe infantile X-linked cardiomyo-
pathic phenotypes, including Barth syndrome with dilated cardio-
myopathy and LVNC in a paediatric population.32,37,38 However,
G4.5 mutations were not found in our adult population with the
autosomal dominant mode of transmission, which suggests that
non-compaction presenting in adulthood may be genetically dis-
tinct from paediatric cases where the disorder is predominantly
X-linked and mutations in G4.5 prevail.32,34,37,38
Mutations in a-dystrobrevin in a family with LVNC and
mutations in ZASP, a gene encoding for the Z-band alternatively
spliced PDZ motif-containing protein, a component of the Z-line
in skeletal and cardiac muscle, were described in patients with
LVNC and LV dysfunction.38,39 In contrast, no mutations in G4.5
and a-dystrobrevin were identified in 47 of 48 patients with
isolated LVNC.40
Non-compaction associated with
chromosomal regions
Loci for LVNC were also described on chromosome 1, 5, and 11
but the specific genes have yet to be identified.41,42
Mutations in sarcomere protein genes
Non-compaction of the left ventricular myocardium seems to be
within the diverse spectrum of cardiac morphologies triggered
Table 2 Diagnostic assessment and therapeutic
strategies
Diagnostic assessment
Doppler
echocardiography
Validated echocardiographic criteria
(Table 1)
Speckle tracking (LV solid body
rotation/twist)
Cardiac MRI Ratio between non-compacted and
compacted layer .2.3
Trabeculated LV mass .20% of the
global LV mass
Genetic testing
Neurological assessment If suspicion of skeletal/mitochondrial
myopathy
Family screening
(fist-degree relatives)
Doppler echocardiography, (genetic
assessment as appropriate)
Electrophysiology study Symptomatic arrhythmias, syncope
Therapeutic strategies
Normal LV size/systolic
function
Regular follow-up (every 2 years)
Heart failure therapy As per guidelines for heart failure
Anticoagulation LVEF ,40%
ICD Secondary prevention/(primary
prevention?)
Biventricular pacing Advanced heart failure/LVEF ,35%/
dyssynchrony (as per guidelines)
ICD, implantable cardioverter/defibrillator; EF, ejection fraction; LV, left
ventricular; MRI, magnetic resonance imaging.
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by sarcomere protein gene defects and there seems to be a shared
molecular aetiology of different cardiomyopathic phenotypes.
Indeed, patients with isolated LVNC, hypertrophic, and dilated car-
diomyopathy share common mutations in sarcomere protein
genes.43–45 A novel missense mutation, pE96K, in the cardiac tro-
ponin T gene (TTNT2) was described in a family with LVNC.46 To
investigate the pathophysiological implications of the mutations,
the researchers generated transgenic mice expressing human wild-
type or human troponin T harbouring the pE96K mutation (mut
cTNT). Interestingly, mut cTNT mice displayed an impaired LV
function and induction of marker genes of heart failure; remark-
ably, LVNC was not observed. This observation supports the
hypothesis that a LVNC phenotype per se is not a prerequisite
for the deterioration of contractile dysfunction and the develop-
ment of cardiomyopathy in this specific mutation. In addition,
the primary defect in LVNC appears to be cardiomyocyte-
autonomous, similar to other genetic cardiomyopathies (e.g.
hypertrophic or dilated cardiomyopathy).46
Non-compaction: a distinct
cardiomyopathy?
The morphological appearance of the myocardium in patients with
LVNC is characteristic and suggests a distinct cardiomyopa-
thy.6,13,47 Genetic testing, however, indicates the lack of a specific
genotype–phenotype association and suggests important genetic
heterogeneity. Indeed, the same mutations can cause different car-
diomyopathic phenotypes: non-compaction can be found with
metabolic diseases and genetic syndromes (e.g. Noonan syndrome,
Barth syndrome) and is associated with different CHDs (e.g.
Ebstein anomaly, pulmonary atresia, aortic stenosis, ventricular
septal defect) although some patients with CHD may not rep-
resent the classical morphological feature of non-compacted
myocardium.6,41,48
Despite major advances in the genetic background and under-
standing of the aetiology of cardiomyopathies, there is a poor
understanding between genotype–phenotype correlation and
many questions regarding phenotypic expression of the same
gene defect are unanswered, yet. There is the reality that a patho-
genetic mutation in the same gene results in a different trabecular
remodelling or maladaptive remodelling response of the embryo-
nic myocardium, which can cause different phenotypes/cardiomyo-
pathies. This raises the question that at least for certain mutations,
hypertrophic, restrictive, dilated cardiomyopathies, and non-
compaction are not clearly distinct clinical and pathophysiological
entities.31,49 Is there a continuum from hypertrophic/dilated
cardiomyopathy and non-compaction? Indeed, Luedde et al.46 chal-
lenged the notion that LVNC phenotype is required for the devel-
opment of cardiomyopathy. Non-compaction of the left
ventricular myocardium may be a secondary consequence of a
genetic alteration, which may be well compensated or present
with heart failure. The marked variations of phenotypes observed
in families indicate that additional, yet unknown modifiers may
determine the clinical and pathophysiological appearance of
LVNC; the extent of LVNC itself may have a disease-modifying
role.28,44,46 This hypothesis is further supported by the description
of seven different phenotypes of LVNC with different outcome.50
The genetic heterogeneity of LVNC, the morphological appear-
ance of LVNC in different metabolic diseases and genetic syn-
dromes, the genetic overlap of different myocardial phenotypes/
cardiomyopathies, and the observations from Luedde et al.,46 do
not allow us to label LVNC as a distinct cardiomyopathy or a
primary myocardial disease.
Multimodality imaging, systematic and comprehensive pedigree
analysis, family screening, and genetic testing are required to
further characterize the morphological expression and myocardial
phenotype of genetic mutations and different underlying diseases,
and to better understand the genotype–phenotype correlation.
This implies that patients with LVNC and their first degree relatives
undergo a comprehensive diagnostic assessment by a multidisci-
plinary team, including cardiologists and geneticists (Table 2).
Epidemiology
The reported prevalence varies considerably and the true preva-
lence of LVNC is unknown. Once considered a rare form of car-
diomyopathy, LVNC is getting increasingly recognized. Major
limitations are the retrospective design of most or all of the
studies and the different inclusion criteria with a considerable
selection bias. Most studies report the prevalence of patients
referred to an echocardiography laboratory at a tertiary care
centre for the evaluation of symptoms, abnormal clinical findings,
or family screening. The prevalence of LVNC referred to echocar-
diography laboratories is reported to be between 0.014
and 1.3%.30,51– 54
In a population-based, retrospective cohort study of primary
cardiomyopathies in Australian children, isolated LVNC accounted
for 9.2% of all cases, identified as the third most frequent cardio-
myopathy after dilated and hypertrophic cardiomyopathies,55 and
this proportion was very similar to that calculated from the
Texas Children’s Hospital echocardiography database (9.5%).52
Among 960 patients seen in a designated heart failure clinic,
heart failure due to ischaemic heart disease, idiopathic dilated car-
diomyopathy, and valvular disease was most common, only a min-
ority of this heart failure population (3%) had isolated LVNC.56
Clinical presentation and outcome
Initial presentation
The spectrum of the initial presentation is wide and non-specific
and depends on many factors: whether LVNC occurs in isolation
or in association with a syndrome, CHD, or other diseases,
whether LVNC is studied in a paediatric or adult population or
whether LVNC is diagnosed in asymptomatic patients during
family screening. Clinical symptoms at initial presentation are
mainly the result of systolic/diastolic ventricular dysfunction and
include non-specific chest pain/discomfort, heart failure symptoms,
or arrhythmias.11,30,35,51– 54,57– 59
The electrocardiographic findings are non-specific. In a compre-
hensive analysis, intraventricular conduction delay (left bundle
branch block!), voltage signs of LV hypertrophy, and repolarization
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abnormalities were most common, but no electrocardiographic
pattern was specific for LVNC at the first presentation.60 An
entirely normal electrocardiogram was present in 13% of the
population (n ¼ 78); these patients were significantly younger,
had less severe structural cardiac abnormalities (except for non-
compaction), and were less likely to present with signs of heart
failure; some patients were asymptomatic family members of
affected patients.60 Whether these findings have prognostic impli-
cations needs to be investigated in long-term controlled studies.
Complications and outcome
The classical triad of heart failure, ventricular arrhythmias, and sys-
temic embolic events constitute typical complications in patients
with a more advanced disease (Table 3). The outcome also
depends on the clinical phenotype.50 Like in most cardiovascular
diseases, we shall never know the natural history of LVNC as
the natural history in most patients is modified by interventions,
such as heart failure therapy and device implantation. Importantly,
outcomes, including morbidity and mortality, vary among the
different reports and are not comparable because of the retro-
spective study design without standardized interventions, selection
bias, different patient populations and disease severity among
others.11,30,35,51–54,57 –59 Heart failure occurs frequently (.50%
of patients) and ventricular tachycardias, cardiovascular deaths,
and sudden cardiac deaths are reported by most investigators
(Table 3); they are less frequently observed in more recent
studies52– 54,57– 59 than in the initial publications.11,30 Adverse out-
comes have been overestimated in earlier reports because of nega-
tive selection bias with inclusion of primarily symptomatic patients
referred to a tertiary care centre. In addition, earlier detection due
to improvements in recognition, imaging technology, and modern
heart failure therapy might have also modified the ‘unnatural’
history of LVNC in the more recent cohorts with a more favour-
able outcome than previously reported.30,54,58,59 Short- and
mid-term outcome data in these studies are consistent with that
of our experiences in asymptomatic patients (unpublished data).
Mortality did not differ significantly between patients with iso-
lated LVNC and control patients with dilated cardiomyopathy
(3-year survival of 85 vs. 83%).53 This supports the hypothesis
that LV dysfunction rather than the phenotype itself (LVNC)
poses the patients at risk for morbidity and mortality.46,53
Prevention of sudden cardiac death
Life-threatening ventricular tachycardias are reported in 20% or
more of the patients and remain a concern for sudden cardiac
death in mostly adults with advanced disease (Table 3). Patients
with LVNC have an arrhythmogenic substrate consisting of suben-
docardial fibrosis probably due to microcirculatory dysfunction
that is not confined to the non-compacted segments.16,30,61 In a
cohort of 12 adults with isolated LVNC and a median follow-up
of 36 months who were treated with an implantable cardiover-
ter/defibrillator (ICD) for secondary prevention (n ¼ 8), appropri-
ate ICD therapy occurred in 50% of the cases.62 In contrast, an
appropriate ICD therapy was only documented in 25% of the
cases with primary prevention. The fact that supraventricular
arrhythmias were documented in two-thirds of the patients with
an ICD does have important implications regarding the
management strategy and selection of devices with reliable detec-
tion enhancements when ICD implantation is considered.62
Predictors of outcome
Identification of strong predictors of outcome is important to
select effective management strategies. Unfortunately, the different
studies are not comparable: the number of patients included in the
different studies is small and the population is heterogeneous (pae-
diatric vs. adult population; LVNC in isolation or associated with
syndromes, CHD and other disorders) so that the identification
of powerful predictors is difficult or impossible. Clinical and echo-
cardiographic predictors are summarized in Table 4.24,30,51,57,59,63
Management
There is no therapy specific for patients with LVNC. Despite limit-
ations of the published risk factors for adverse outcomes, they are
helpful to guide treatment, including medical therapy and device
therapy (Table 4). Although so far unproven by prospective
studies, timely institution of evidence-based standard heart failure
treatment in asymptomatic patients with worsening LV systolic
function may prevent the occurrence of complications. We apply
the current guidelines for the management of heart failure to
our patients with LVNC as LV dysfunction rather than the pheno-
type might pose the patients at risk.53,64,65
Anticoagulation?
Prevention of embolic complications is an important management
goal and remains a matter of debate in these patients. Biased by
early reports with a high rate of embolic events, we were more
aggressive to administer anticoagulants independent of ventricular
systolic function.30 As we have never seen thrombo-embolic com-
plications in a patient in sinus rhythm and with normal systolic
function, and as the knowledge about the risk of embolic compli-
cations has improved in this population, we are less rigorous to
initiate anticoagulation therapy. Because deep intertrabecular
recesses with slow/sluggish blood flow aggravate the risk of
thrombus formation, we recommend anticoagulation (target INR
2.0–3.0) in patients with impaired systolic function (LV ejection
fraction ,40%), being aware of the absence of any robust data
to support this approach. Anticoagulation therapy, however,
must be targeted to the individual patient after careful assessment
of the benefit and risks.
ICD/biventricular pacing?
As long as there are no robust data whether the current guidelines
for device therapy, including ICD and biventricular pacing, apply to
patients with LVNC, current practice guidelines are helpful for
management strategies.66,67 The number of patients included in a
retrospective study is too small to elaborate hypotheses regarding
clinical parameters of patients with isolated LVNC that predict risk
for sudden death.62 It is our practice to perform an EP study in all
patients with LVNC and symptomatic arrhythmias or syncope to
assess whether ventricular or supraventricular arrhythmias are
inducible. In the present state of knowledge, an ICD should be
implanted in patients with LVNC presenting with syncope, sympto-
matic ventricular arrhythmias or with severely impaired LV systolic
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Table 3 Clinical characteristics of left ventricular non-compaction
Chin11 Ichida35 Oechslin30 Pignatelli52 Wald57 Murphy58 Lofiego59 Aras51 Lilje54 Stanton53
Isolated form Yes Yes Yes Noa Yes Yes Yes Yes Noa Yes
Number of patients 8 27 34 36 22 45 65 67 66 30
Males, % 63 56 74 56 41 62 66 52 60
Population Paediatric Paediatric Adult Paediatric Paediatric Adult Adult Adult Paediatric Adult
Median age at diagnosis
(range), years
7.3 (11 months–
22.5 years)
5 (1 week–15
years)
40 (16–71) 90 days (1 day–17
years)
Mean 3.9
(0–16)
Mean 37
(13–83)
Mean
45+16
41+18
(16–75)
4 (0–21) Mean 39+19.5
(16–83)
Follow-up (median), years ≤5 ≤17 (6) ≤11 (3) ≤12 (3.2) ≤16 (3) ,15 (2.7) ≤16 (21) ≤4 (mean
2.5)
≤4.3 (1) Mean 2.5+1.2
Familial occurrence, % 50 44 18 19b 18b 51c 31 33 — —
Localization of non-compacted myocardium (%)
Apex Most prominent 100 94 — Most
common
— Most
common
100 — Most common
Mid-ventricular inferior
wall
70 94 — Most
common
— 90 — Most common
Mid-ventricular lateral
wall
41 100 — Most
common
— .90 — Most common
Complications (%)
Heart failure 63 30 68 .50d 91 67 34 34 68 —
VT 38 0 41 3 23 20e 6 36 20 27e
Systemic embolic events 38 0 21 0 0 4 5 9 14 0
Cardiovascular death
(SD)
38 (13) 7 (0) 35 (18) 14 (3) 14 (5) 2 (2) 10 (5) 15 (9) 7 (0) 10
Heart Tx 0 4f 12 11 9 0 14 0 0 0
Heart Tx, heart transplantation; SD, sudden death; VT, ventricular tachycardia.
aAssociated congenital cardiac anomalies included ventricular septal defect, pulmonary valvular stenosis, Ebstein anomaly, left ventricular outflow tract obstruction/hypoplastic left heart syndrome.
bPositive family history for cardiomyopathy (dilated cardiomyopathy, hypertrophic cardiomyopathy, and non-compaction).
cFamily history of dilated cardiomyopathy and left ventricular non-compaction.
dPatients with LV ejection fraction ,50%.
eNon-sustained VT on Holter-ECG.
fOne patient was a candidate for heart transplantation.
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function (LVEF ,35%). Atrial flutter/atrial fibrillation are common
and intermittent supraventricular arrhythmias were observed in
66% of patients on interrogation of the device; devices with
reliable detection and therapy enhancements should be primarily
considered in these patients.62
Summary
Knowledge and understanding about aetiology, embryogenesis of
the myocardium, genetic background, diagnosis and outcome of
LVNC have steadily improved. Non-compaction of the left ventri-
cular myocardium best appreciates evolutionary background and is
the appropriate term to describe the distinct morphological
appearance of a thickened, two-layered myocardium with an epi-
cardial compacted and a much thicker endocardial non-compacted
layer.
Non-compaction of the left ventricular myocardium with poor
genotype–phenotype correlation seems to be a distinct myocar-
dial phenotype with genetic heterogeneity: it does not seem to
be a distinct cardiomyopathy, but rather a morphological
expression of different diseases. Non-compaction of the left ventri-
cular myocardium is within a diverse spectrum of myocardial mor-
phologies/cardiomyopathies triggered by gene defects/mutations:
the causal role of LVNC in the pathogenesis of a distinct cardio-
myopathy is questionable. Whether LVNC in isolation or in associ-
ation with other pathologies (e.g. CHD, genetic syndromes) has a
similar or completely different molecular/genetic basis, pathobiol-
ogy, and natural course, and whether different mechanisms,
environmental factors, yet unknown modifiers, and pathophysiolo-
gical mechanisms account for different entities of LVNC despite a
characteristic morphological appearance, remain a matter of
further research.
Echocardiographers and clinicians have to be cautioned not to
overdiagnose LVNC. Non-compaction of the left ventricular myo-
cardium may reflect a morphological trait and there is a grey zone
between a normal variant and a pathological myocardial structure
with clinical relevance. A comprehensive diagnostic assessment,
including multimodality imaging, a systematic screening of first-
degree relatives, and a comprehensive clinical, and genetic assess-
ment by a multidisciplinary team may provide the information to
determine whether LVNC is just a morphological expression or
phenotypic variant of other cardiomyopathies of a primary
genetic disorder.
Conflict of interest: none declared.
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